Adenocarcinoma
MONDO:0004970A common cancer characterized by the presence of malignant glandular cells. Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous). Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.
Also known as: adenocarcinoma, adenocarcinoma NOS (morphologic abnormality), adenocarcinoma, malignant, adenocarcinoma, no subtype (morphologic abnormality), adenocarcinomas, ADNOS
7737 clinical trials for this condition and its sub-types, 184 tagged with Adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Adenocarcinoma
-
Hepatocellular carcinoma 1,043 trials · 1,088 incl. sub-types
8 sub-types
- Hepatoblastoma 42 trials Sub-types →
- Pediatric hepatocellular carcinoma 36 trials
- Fibrolamellar hepatocellular carcinoma 15 trials Sub-types →
- Adult hepatocellular carcinoma 12 trials
- Aflatoxin-related hepatocellular carcinoma 0 trials
- Hepatocellular clear cell carcinoma 0 trials
- Liver diffuse large B-cell lymphoma 0 trials
- Sclerosing hepatic carcinoma 0 trials
-
Pancreatic adenocarcinoma 493 trials · 926 incl. sub-types
5 sub-types
- Pancreatic ductal adenocarcinoma 552 trials Sub-types →
- Pancreatic acinar cell carcinoma 12 trials Sub-types →
- Pancreatic intraductal papillary-mucinous neoplasm with an associated invasive carcinoma 1 trial
- Mucinous pancreas adenocarcinoma 0 trials
- Pancreatic cystadenocarcinoma 0 trials Sub-types →
-
Renal cell carcinoma 611 trials · 710 incl. sub-types
11 sub-types
- Renal cell adenocarcinoma 98 trials · 250 incl. sub-types Sub-types →
- Nonpapillary renal cell carcinoma 156 trials · 246 incl. sub-types Sub-types →
- Adrenal cortex carcinoma 42 trials Sub-types →
- Collecting duct carcinoma 17 trials
- Kidney medullary carcinoma 10 trials · 13 incl. sub-types Sub-types →
- MIT family translocation renal cell carcinoma 6 trials Sub-types →
- Wolffian duct adenocarcinoma 2 trials
- Acquired cystic disease-associated renal cell carcinoma 0 trials
- Cystic renal cell carcinoma 0 trials
- Mucinous tubular and spindle renal cell carcinoma 0 trials
- Renal pelvis adenocarcinoma 0 trials
-
Tubular adenocarcinoma 0 trials · 557 incl. sub-types
4 sub-types
- Pancreatic ductal adenocarcinoma 552 trials Sub-types →
- Invasive tubular breast carcinoma 5 trials
- Gastric tubular adenocarcinoma 0 trials
- Well-differentiated fetal adenocarcinoma of the lung 0 trials
-
Colorectal adenocarcinoma 246 trials · 546 incl. sub-types
5 sub-types
- Rectum adenocarcinoma 231 trials · 232 incl. sub-types Sub-types →
- Colon adenocarcinoma 90 trials · 121 incl. sub-types Sub-types →
- Colorectal signet ring cell carcinoma 0 trials · 3 incl. sub-types Sub-types →
- Colorectal serrated adenocarcinoma 1 trial
- Colorectal medullary carcinoma 0 trials Sub-types →
-
Gastroesophageal junction adenocarcinoma 506 trials
-
Gastric adenocarcinoma 448 trials · 480 incl. sub-types
9 sub-types
- Microinvasive gastric cancer 28 trials
- Diffuse gastric adenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Gastric cardia adenocarcinoma 4 trials
- Signet ring cell gastric adenocarcinoma 2 trials
- CTNNA1-related diffuse gastric and lobular breast cancer syndrome 0 trials
- Gastric intestinal type adenocarcinoma 0 trials
- Gastric papillary adenocarcinoma 0 trials
- Gastric tubular adenocarcinoma 0 trials
- Mucinous gastric adenocarcinoma 0 trials
-
Bile duct adenocarcinoma 17 trials · 416 incl. sub-types
1 sub-type
- Extrahepatic bile duct adenocarcinoma 2 trials · 406 incl. sub-types Sub-types →
-
Prostate adenocarcinoma 297 trials
2 sub-types
- Prostate adenoid cystic carcinoma 0 trials
- Prostatic acinar adenocarcinoma 0 trials Sub-types →
-
Breast adenocarcinoma 36 trials · 278 incl. sub-types
13 sub-types
- Breast ductal adenocarcinoma 18 trials · 191 incl. sub-types Sub-types →
- Breast lobular carcinoma 13 trials · 34 incl. sub-types Sub-types →
- Inflammatory breast carcinoma 29 trials
- Lobular breast carcinoma in situ 27 trials
- Mixed lobular and ductal breast carcinoma 1 trial Sub-types →
- Adenoid cystic breast carcinoma 0 trials
- Breast malignant eccrine spiradenoma 0 trials
- Breast mucinous cystadenocarcinoma 0 trials
- Mammary Paget disease 0 trials Sub-types →
- Mucoepidermoid breast carcinoma 0 trials
- Oncocytic breast carcinoma 0 trials
- Sebaceous breast carcinoma 0 trials
- Signet ring cell breast carcinoma 0 trials
-
Serous adenocarcinoma 6 trials · 241 incl. sub-types
6 sub-types
- Ovarian serous adenocarcinoma 198 trials · 202 incl. sub-types Sub-types →
- Fallopian tube serous adenocarcinoma 71 trials
- Peritoneal serous adenocarcinoma 2 trials · 39 incl. sub-types Sub-types →
- Endometrial serous adenocarcinoma 36 trials
- Serous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Cervical serous adenocarcinoma 0 trials Sub-types →
-
Ovarian adenocarcinoma 12 trials · 230 incl. sub-types
7 sub-types
- Ovarian serous adenocarcinoma 198 trials · 202 incl. sub-types Sub-types →
- Ovarian endometrioid adenocarcinoma 77 trials Sub-types →
- Ovarian clear cell adenocarcinoma 22 trials · 26 incl. sub-types Sub-types →
- Ovarian mucinous adenocarcinoma 11 trials · 14 incl. sub-types Sub-types →
- Ovarian cystadenocarcinoma 0 trials · 5 incl. sub-types Sub-types →
- Krukenberg carcinoma 1 trial
- Rete ovarii adenocarcinoma 0 trials
-
Clear cell adenocarcinoma 14 trials · 201 incl. sub-types
11 sub-types
- Clear cell renal carcinoma 140 trials · 142 incl. sub-types Sub-types →
- Ovarian clear cell adenocarcinoma 22 trials · 26 incl. sub-types Sub-types →
- Endometrial clear cell adenocarcinoma 21 trials
- Fallopian tube clear cell adenocarcinoma 18 trials
- Cervical clear cell adenocarcinoma 4 trials Sub-types →
- Bladder clear cell adenocarcinoma 1 trial Sub-types →
- Hidradenocarcinoma 1 trial Sub-types →
- Urethra clear cell adenocarcinoma 1 trial
- Extrahepatic bile duct clear cell adenocarcinoma 0 trials Sub-types →
- Glycogen-rich clear cell breast carcinoma 0 trials
- Hepatocellular clear cell carcinoma 0 trials
-
Esophageal adenocarcinoma 168 trials · 172 incl. sub-types
3 sub-types
- Barrett adenocarcinoma 6 trials
- Esophageal adenoid cystic carcinoma 0 trials
- Mucoepidermoid esophageal carcinoma 0 trials
-
Adenocarcinoma in situ 10 trials · 170 incl. sub-types
3 sub-types
- Ductal breast carcinoma in situ 152 trials Sub-types →
- Lobular breast carcinoma in situ 27 trials
- Lung adenocarcinoma in situ 1 trial
-
Endometrioid adenocarcinoma 12 trials · 144 incl. sub-types
6 sub-types
- Ovarian endometrioid adenocarcinoma 77 trials Sub-types →
- Endometrial endometrioid adenocarcinoma 55 trials Sub-types →
- Fallopian tube endometrioid adenocarcinoma 30 trials
- Stage I endometrioid carcinoma 16 trials
- Stage II endometrioid carcinoma 2 trials
- Cervical endometrioid adenocarcinoma 0 trials Sub-types →
-
Endometrium adenocarcinoma 30 trials · 118 incl. sub-types
9 sub-types
- Ovarian endometrioid adenocarcinoma 77 trials Sub-types →
- Endometrial clear cell adenocarcinoma 21 trials
- Endometrial mixed adenocarcinoma 10 trials
- Endometrial mucinous adenocarcinoma 2 trials
- Endometrial endometrioid adenocarcinoma with spindled epithelial cells 0 trials
- Mucin-rich endometrial endometrioid adenocarcinoma 0 trials
- Oxyphilic endometrial endometrioid adenocarcinoma 0 trials
- Secretory uterine corpus endometrioid adenocarcinoma 0 trials
- Villoglandular endometrial endometrioid adenocarcinoma 0 trials
-
Thyroid gland adenocarcinoma 0 trials · 118 incl. sub-types
3 sub-types
- Thyroid gland follicular carcinoma 20 trials · 77 incl. sub-types Sub-types →
- Thyroid gland papillary carcinoma 59 trials · 60 incl. sub-types Sub-types →
- Thyroid gland mucoepidermoid carcinoma 0 trials
-
Lung adenocarcinoma 114 trials · 117 incl. sub-types
11 sub-types
- Minimally invasive lung adenocarcinoma 9 trials Sub-types →
- Lung adenocarcinoma in situ 1 trial
- Lung signet ring cell carcinoma 1 trial
- Acinar lung adenocarcinoma 0 trials
- Lung adenoid cystic carcinoma 0 trials
- Lung colloid adenocarcinoma 0 trials Sub-types →
- Lung combined type small cell adenocarcinoma 0 trials
- Lung occult adenocarcinoma 0 trials
- Papillary lung adenocarcinoma 0 trials
- Solid adenocarcinoma with mucin production 0 trials
- Well-differentiated fetal adenocarcinoma of the lung 0 trials
-
Gastroesophageal adenocarcinoma 93 trials
-
Papillary adenocarcinoma 2 trials · 92 incl. sub-types
11 sub-types
- Thyroid gland papillary carcinoma 59 trials · 60 incl. sub-types Sub-types →
- Papillary renal cell carcinoma 25 trials · 27 incl. sub-types Sub-types →
- Ovarian serous surface papillary adenocarcinoma 2 trials
- Breast papillary carcinoma 1 trial Sub-types →
- Papillary eccrine carcinoma 1 trial Sub-types →
- Fallopian tube papillary adenocarcinoma 0 trials
- Gallbladder papillary neoplasm with an associated invasive carcinoma 0 trials
- Gastric papillary adenocarcinoma 0 trials
- Papillary cystadenocarcinoma 0 trials Sub-types →
- Papillary lung adenocarcinoma 0 trials
- Papillary thymic adenocarcinoma 0 trials
-
Fallopian tube adenocarcinoma 4 trials · 81 incl. sub-types
5 sub-types
- Fallopian tube serous adenocarcinoma 71 trials
- Fallopian tube endometrioid adenocarcinoma 30 trials
- Fallopian tube clear cell adenocarcinoma 18 trials
- Fallopian tube mucinous adenocarcinoma 9 trials
- Fallopian tube papillary adenocarcinoma 0 trials
-
Small intestine adenocarcinoma 18 trials · 60 incl. sub-types
2 sub-types
- Duodenal adenocarcinoma 9 trials · 44 incl. sub-types Sub-types →
- Jejunal adenocarcinoma 0 trials
-
Mucinous adenocarcinoma 18 trials · 57 incl. sub-types
17 sub-types
- Colon mucinous adenocarcinoma 2 trials · 21 incl. sub-types Sub-types →
- Ovarian mucinous adenocarcinoma 11 trials · 14 incl. sub-types Sub-types →
- Fallopian tube mucinous adenocarcinoma 9 trials
- Mucinous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Endometrial mucinous adenocarcinoma 2 trials
- Mucoepidermoid carcinoma 2 trials Sub-types →
- Breast mucinous carcinoma 1 trial Sub-types →
- Cervical mucinous adenocarcinoma 0 trials · 1 incl. sub-types Sub-types →
- Rectum mucinous adenocarcinoma 1 trial Sub-types →
- Acinar prostate mucinous adenocarcinoma 0 trials
- Colloid carcinoma of the pancreas 0 trials
- Extrahepatic bile duct mucinous adenocarcinoma 0 trials Sub-types →
- Gallbladder mucinous adenocarcinoma 0 trials
- Lung colloid adenocarcinoma 0 trials Sub-types →
- Mucinous gastric adenocarcinoma 0 trials
- Mucinous pancreas adenocarcinoma 0 trials
- Salivary gland mucinous adenocarcinoma 0 trials
-
Adenoid cystic carcinoma 46 trials · 47 incl. sub-types
17 sub-types
- Paranasal sinus adenoid cystic carcinoma 5 trials Sub-types →
- Salivary gland adenoid cystic carcinoma 3 trials Sub-types →
- Bartholin gland adenoid cystic carcinoma 0 trials
- Adenoid cystic breast carcinoma 0 trials
- Adenoid cystic carcinoma of oropharynx 0 trials
- Adenoid cystic carcinoma of the corpus uteri 0 trials
- Cervical adenoid cystic carcinoma 0 trials
- Cutaneous adenocystic carcinoma 0 trials
- Esophageal adenoid cystic carcinoma 0 trials
- Lacrimal gland adenoid cystic carcinoma 0 trials
- Laryngeal adenoid cystic carcinoma 0 trials
- Lung adenoid cystic carcinoma 0 trials
- Lymph node adenoid cystic carcinoma 0 trials
- Pharyngeal adenoid cystic carcinoma 0 trials
- Prostate adenoid cystic carcinoma 0 trials
- Tracheal adenoid cystic carcinoma 0 trials
- Vaginal adenoid cystic carcinoma 0 trials
-
Cervical adenocarcinoma 27 trials · 34 incl. sub-types
10 sub-types
- Cervical adenosquamous carcinoma 16 trials Sub-types →
- Cervical clear cell adenocarcinoma 4 trials Sub-types →
- Endocervical adenocarcinoma 3 trials
- Wolffian duct adenocarcinoma 2 trials
- Cervical mucinous adenocarcinoma 0 trials · 1 incl. sub-types Sub-types →
- Cervical adenoid cystic carcinoma 0 trials
- Cervical endometrioid adenocarcinoma 0 trials Sub-types →
- Cervical serous adenocarcinoma 0 trials Sub-types →
- Early invasive cervical adenocarcinoma 0 trials
- Uterine ligament adenocarcinoma 0 trials Sub-types →
-
Acinar cell carcinoma 4 trials · 15 incl. sub-types
5 sub-types
- Pancreatic acinar cell carcinoma 12 trials Sub-types →
- Acinic cell breast carcinoma 0 trials
- Parotid gland acinic cell carcinoma 0 trials
- Prostatic acinar adenocarcinoma 0 trials Sub-types →
- Salivary gland acinic cell carcinoma 0 trials
-
Signet ring cell carcinoma 4 trials · 11 incl. sub-types
11 sub-types
- Colorectal signet ring cell carcinoma 0 trials · 3 incl. sub-types Sub-types →
- Signet ring cell gastric adenocarcinoma 2 trials
- Krukenberg carcinoma 1 trial
- Lung signet ring cell carcinoma 1 trial
- Acinar prostate adenocarcinoma, signet ring variant 0 trials
- Bladder signet ring cell adenocarcinoma 0 trials
- Extrahepatic bile duct signet ring cell carcinoma 0 trials Sub-types →
- Gallbladder signet ring cell adenocarcinoma 0 trials
- Pancreatic signet ring cell adenocarcinoma 0 trials
- Signet ring cell breast carcinoma 0 trials
- Signet ring cell variant cervical mucinous adenocarcinoma 0 trials
-
Gallbladder adenocarcinoma 9 trials
4 sub-types
-
Paget disease 2 trials · 9 incl. sub-types
5 sub-types
- Extramammary Paget disease 7 trials Sub-types →
- Cutaneous Paget disease 0 trials · 1 incl. sub-types Sub-types →
- Mammary Paget disease 0 trials Sub-types →
- Osteosarcoma arising in bone Paget disease 0 trials
- Scrotum Paget disease 0 trials
-
Bladder adenocarcinoma 5 trials · 8 incl. sub-types
7 sub-types
- Bladder urachal adenocarcinoma 5 trials
- Bladder clear cell adenocarcinoma 1 trial Sub-types →
- Bladder mixed adenocarcinoma 1 trial
- Bladder colloid adenocarcinoma 0 trials
- Bladder colonic type adenocarcinoma 0 trials
- Bladder hepatoid adenocarcinoma 0 trials
- Bladder signet ring cell adenocarcinoma 0 trials
-
Vaginal adenocarcinoma 7 trials
1 sub-type
- Vaginal adenoid cystic carcinoma 0 trials
-
Diffuse type adenocarcinoma 1 trial · 6 incl. sub-types
1 sub-type
- Diffuse gastric adenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
-
Cystadenocarcinoma 0 trials · 6 incl. sub-types
6 sub-types
- Mucinous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Ovarian cystadenocarcinoma 0 trials · 5 incl. sub-types Sub-types →
- Serous cystadenocarcinoma 1 trial · 5 incl. sub-types Sub-types →
- Biliary cystadenocarcinoma 0 trials
- Pancreatic cystadenocarcinoma 0 trials Sub-types →
- Papillary cystadenocarcinoma 0 trials Sub-types →
-
Vulvar adenocarcinoma 3 trials · 5 incl. sub-types
7 sub-types
- Vulval Paget disease 2 trials
- Bartholin gland adenocarcinoma 0 trials Sub-types →
- Adenocarcinoma of skene gland origin 0 trials
- Vulvar apocrine adenocarcinoma 0 trials
- Vulvar clear cell hidradenocarcinoma 0 trials
- Vulvar eccrine adenocarcinoma 0 trials Sub-types →
- Vulvar sebaceous carcinoma 0 trials
-
Parathyroid gland carcinoma 4 trials
-
Pituitary adenocarcinoma 3 trials
3 sub-types
-
Sebaceous adenocarcinoma 2 trials · 3 incl. sub-types
3 sub-types
- Ocular sebaceous carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Sebaceous breast carcinoma 0 trials
- Vulvar sebaceous carcinoma 0 trials
-
Hepatoid adenocarcinoma 2 trials
1 sub-type
- Bladder hepatoid adenocarcinoma 0 trials
-
Mesonephric adenocarcinoma 2 trials
1 sub-type
- Wolffian duct adenocarcinoma 2 trials
-
Sweat gland carcinoma 1 trial · 2 incl. sub-types
4 sub-types
- Apocrine adenocarcinoma 2 trials Sub-types →
- Eccrine carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Hidradenocarcinoma 1 trial Sub-types →
- Cutaneous adenocystic carcinoma 0 trials
-
Urethra adenocarcinoma 1 trial · 2 incl. sub-types
1 sub-type
-
Micropapillary serous carcinoma 1 trial
-
Nasal cavity adenocarcinoma 1 trial
-
Seminal vesicle adenocarcinoma 1 trial
-
Trabecular adenocarcinoma 1 trial
-
Ureter adenocarcinoma 1 trial
-
Adenoacanthoma 0 trials
-
Epididymal adenocarcinoma 0 trials
-
Ethmoid sinus adenocarcinoma 0 trials
-
Granular cell carcinoma 0 trials
-
Intestinal type adenocarcinoma 0 trials
2 sub-types
-
Lacrimal gland adenocarcinoma 0 trials
2 sub-types
-
Maxillary sinus adenocarcinoma 0 trials
-
Middle ear adenocarcinoma 0 trials
-
Minor salivary gland adenocarcinoma 0 trials
1 sub-type
-
Rete testis adenocarcinoma 0 trials
-
Scirrhous adenocarcinoma 0 trials
-
Submandibular gland adenocarcinoma 0 trials
-
Thymus gland adenocarcinoma 0 trials
2 sub-types
- Papillary thymic adenocarcinoma 0 trials
- Thymic mucoepidermoid carcinoma 0 trials
-
Villous adenocarcinoma 0 trials
2 sub-types
Most studied deeper sub-types
-
Triple therapy aims to boost survival in Hard-to-Treat stomach cancers
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted drug zolbetuximab to standard immunotherapy (pembrolizumab) and chemotherapy can help people with advanced stomach or gastroesophageal junction (GEJ) cancer live longer. The study enrolls 500 adults whose tumors have specific m…
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New gene therapy injection aims to boost prostate cancer radiation results
Disease control Recruiting nowThis study tests a gene therapy called aglatimagene besadenovec, given with valacyclovir, in 45 men with intermediate-risk prostate cancer who will also receive radiation. The main goal is to see how the therapy spreads in the body and to measure immune responses and tumor marker…
Phase 2 • Sponsor: Candel Therapeutics, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug targets stomach and pancreatic cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called ASP2138, which helps the immune system attack cancer cells that have a specific marker (CLDN18.2). It is for people with advanced stomach, gastroesophageal junction (GEJ), or pancreatic cancer that cannot be removed by surgery or has…
Phase 1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Immune-Targeting drug could boost stomach cancer treatment
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug ASP2138 to standard chemotherapy and immunotherapy (pembrolizumab) helps people with a specific type of advanced stomach or gastroesophageal junction cancer live longer without their disease worsening. The study enroll…
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New targeted therapy combo aims to fight stubborn stomach cancers
Disease control Recruiting nowThis Phase 3 trial is testing whether a new targeted drug called sonesitatug vedotin, combined with chemotherapy (capecitabine) and possibly an immunotherapy (rilvegostomig), can help people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specifi…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with genetic flaw
Disease control Recruiting nowThis study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 adults whose cancer has not responded to standar…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a platform trial match the right drug combo to each tumor?
Disease control Recruiting nowThis phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…
Phase 1/2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could your own tumor cells beat lung cancer? new trial tests it
Disease control Recruiting nowThis study takes white blood cells from a patient's lung tumor, grows them in large numbers in the lab, and gives them back to the patient to fight the cancer. The goal is to see if these specially selected cells can shrink tumors in people with advanced non-small cell lung cance…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New pill HLD-0915 takes on tough prostate cancer
Disease control Recruiting nowThis study tests an experimental oral drug called HLD-0915 in men with metastatic prostate cancer that has worsened after other treatments. The trial has two phases: Phase 1 checks safety and the best dose, while Phase 2 looks at how well it controls the cancer. About 190 men wil…
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New study tracks safety of VYLOY in everyday cancer care
Disease control Recruiting nowThis study monitors 377 South Korean patients with advanced stomach or gastroesophageal junction cancer who receive VYLOY (zolbetuximab) as part of their normal treatment. Researchers will track side effects and how long the cancer stays stable. The goal is to confirm the drug's …
Sponsor: Astellas Pharma Korea, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs—docetaxel (chemotherapy) and a radioactive compound called 177Lu-PSMA-I&T—in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose of docetaxel when used with the r…
Phase 1 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: enhertu studied in 20+ tumor types
Disease control Recruiting nowThis study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug infusion targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new drug combo tame resistant prostate cancer?
Disease control Recruiting nowThis phase 2 trial is testing whether an investigational oral drug called MRT-2359, when combined with the standard prostate cancer drug apalutamide, can lower PSA levels in men with castration-resistant prostate cancer. The study includes about 25 adults with a specific genetic …
Phase 2 • Sponsor: Monte Rosa Therapeutics, Inc • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…
Phase 1 • Sponsor: Duboce Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for tough prostate cancer: drug combo aims to delay progression
Disease control Recruiting nowThis study tests whether the drug talazoparib, given alone or with enzalutamide, can slow down cancer growth in men with a certain type of advanced prostate cancer that has stopped responding to a previous treatment called abiraterone. About 126 participants with specific gene ch…
Phase 2 • Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for pancreatic cancer: experimental combo trial launches
Disease control Recruiting nowThis study tests whether adding the drug relacorilant to standard chemotherapy can help people with metastatic pancreatic cancer live longer without their disease getting worse. About 60 adults who have not yet been treated for advanced pancreatic cancer will receive the combinat…
Phase 2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Immunotherapy plus chemotherapy before surgery shows promise against tough stomach cancers
Disease control Recruiting nowThis trial investigates whether adding the immunotherapy drug serplulimab (HLX10) to standard chemotherapy (S-1 and oxaliplatin) before and after surgery can improve outcomes for people with locally advanced, PD-L1-positive stomach or gastroesophageal junction cancer. Participant…
Phase 2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill takes on Hard-to-Treat prostate cancer in early human trial
Disease control Recruiting nowThis early-phase study is testing a new daily pill called ACE-232 in 67 men with metastatic castration-resistant prostate cancer that has stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of whether …
Phase 1 • Sponsor: Acerand Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Major trial tests best way to boost radiation for prostate cancer
Disease control Recruiting nowThis study is testing whether adding a focused radiation boost after standard short-course radiotherapy improves outcomes for men with localized prostate cancer. About 1,200 men will be randomly assigned to receive either standard SBRT alone or SBRT plus one of three boost method…
Phase 2/3 • Sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New combo therapy aims to shrink rectal tumors before surgery
Disease control Recruiting nowThis phase 2 trial will test whether adding immunotherapy drugs (cemiplimab alone or with fianlimab or REGN7075) to standard chemotherapy (capecitabine and oxaliplatin) can completely eliminate tumors in patients with locally advanced rectal cancer before surgery. The study plans…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can a Hormone-Radiation combo save erectile function in prostate cancer?
Disease control Recruiting nowThis phase 2 trial is testing whether combining a 12-month course of the hormone therapy Relugolix with precise, image-guided radiation can help men with intermediate-risk prostate cancer recover erectile function. Fifty men will receive the treatment and complete questionnaires …
Phase 2 • Sponsor: National Cancer Institute, Naples • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could MRI replace CT for sharper cancer radiation planning?
Disease control Recruiting nowThis study investigates whether using magnetic resonance imaging (MRI) instead of standard CT scans to plan radiation therapy can improve treatment accuracy and reduce side effects. It enrolls adults with prostate, liver, or head and neck cancers who need radiation. Researchers w…
Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a simple vacuum dressing prevent infections after rectal cancer surgery?
Disease control Recruiting nowThis study tests whether a special vacuum dressing (PICO 7®) placed on the surgical wound can reduce infections after rectal cancer surgery. About 100 adults who have had chemoradiotherapy followed by abdominoperineal resection will be enrolled. The device is designed to drain fl…
Sponsor: Centre Hospitalier Departemental Vendee • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental drug targets Hard-to-Treat salivary gland cancers
Disease control Recruiting nowThis phase 2 trial tests whether the drug sacituzumab govitecan can help control salivary gland cancer that has come back or spread to other parts of the body. About 30 adults whose cancer cannot be removed by surgery or cured with radiation will receive the drug through an IV. R…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New trial: could adding chemo to hormone therapy stop prostate cancer from spreading?
Disease control Recruiting nowThis phase 3 trial is testing whether adding the chemotherapy drug docetaxel to standard hormone therapy (ADT plus an ARPI) can lower the chance of prostate cancer growing or spreading. The study enrolls 830 men with metastatic prostate cancer that is sensitive to hormone therapy…
Phase 3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New pill shows promise against tough cancers in early trial
Disease control Recruiting nowThis study tests a new oral drug called NXP900 in people with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The trial has two parts: first, finding the right dose, and then seeing if the drug shrinks tumors. It is a fir…
Phase 1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for stomach cancer: experimental drug BHB810 enters human trials
Disease control Recruiting nowThis study tests a new drug, BHB810, in adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The drug is given as an IV infusion every two weeks. The main goals are to check safety and find the best dose, while also seein…
Phase 1/2 • Sponsor: BigHat Biosciences, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Lymph node surgery may boost cervical cancer treatment
Disease control Recruiting nowThis study looks at whether surgically removing para-aortic lymph nodes before standard chemoradiation can improve disease-free survival in people with stage IIIC1 cervical cancer. About 510 participants will be randomly assigned to either standard treatment or surgery plus tailo…
Phase 3 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New adaptive radiation aims to spare bladder in prostate cancer patients
Disease control Recruiting nowThis study is testing a new type of radiation therapy that adapts to changes in the prostate and bladder during each treatment session. It is for men with localized prostate cancer who also have an enlarged prostate or urinary symptoms. The goal is to see if this approach can red…
Sponsor: University of Zurich • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New biologic TRK-950 joins forces with standard chemo to fight stomach cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental biologic called TRK-950 to the standard combination of ramucirumab and paclitaxel helps people with advanced stomach or gastroesophageal junction cancer. Participants receive either the standard two-drug regimen or the stand…
Phase 2 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for stomach cancer: targeted drug combo enters final testing
Disease control Recruiting nowThis Phase 3 trial is testing whether a new drug combination (tecotabart vedotin plus tislelizumab) works better than standard chemotherapy for people with advanced stomach cancer that has a specific protein called CLDN18.2. The study plans to enroll 752 participants who have not…
Phase 3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill targets hard-to-treat cancers with specific gene flaw
Disease control Recruiting nowThis study tests a new experimental drug called PLX-61639 for people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken as a daily pill and aims to shrink or control the cancer. A…
Phase 1 • Sponsor: Plexium, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called MORAb-202 that targets a protein (folate receptor alpha) found on some cancer cells. It is for people with ovarian, endometrial, non-small cell lung, or triple-negative breast cancer. The trial has two parts: first to find the safest dose, then …
Phase 1/2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called repotrectinib in people with advanced solid tumors that have certain gene changes (ALK, ROS1, or NTRK). The trial has two parts: first, finding a safe dose, and second, seeing how well the drug shrinks tumors. About 500 adults with advanced canc…
Phase 1/2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy aims to shrink untreatable liver tumors
Disease control Recruiting nowThis study tests a powerful combination of treatments for people with advanced liver cancer that cannot be surgically removed. The approach uses heat-based ablation to destroy the main tumor, followed by targeted therapy (lenvatinib), immunotherapy (tislelizumab), and a procedure…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail aims to shrink rectal tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests whether adding two targeted drugs (tucatinib and trastuzumab) to standard chemotherapy can shrink HER2-positive rectal tumors before surgery. About 37 adults with locally advanced rectal cancer will receive the drug combo for 6 weeks, then continue it wit…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New immunotherapy combo may let older colorectal cancer patients skip surgery
Disease control Recruiting nowThis study tests whether immunotherapy drugs (cemiplimab alone or with fianlimab) can shrink or eliminate tumors in older patients (70+) or those unfit for surgery with a specific genetic type of colorectal cancer (MSI-H). The goal is to avoid surgery if the cancer disappears com…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo aims to shrink tough stomach cancers
Disease control Recruiting nowThis Phase 2 trial tests whether adding the immunotherapy drug ivonescimab to standard chemotherapy can improve tumor shrinkage in people with advanced or metastatic stomach or gastroesophageal cancer. About 88 participants will receive treatment every two weeks. The main goal is…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug combo shows promise for rare salivary gland cancer
Disease control Recruiting nowThis study tests a new drug (MRG003) alone or with another drug (putrelimab) in people with salivary gland cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or stop them from growing. About 90 adults will take part, and the study is not…
Phase 2 • Sponsor: Ji Dongmei • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Smart radiation aims to zap prostate cancer recurrence with fewer side effects
Disease control Recruiting nowThis study tests a smarter way to give radiation to men whose prostate cancer has come back after surgery. Using advanced scans, doctors will give higher radiation doses to the spots where cancer is active and lower doses to healthy areas. The goal is to control the cancer while …
Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy aims to boost prostate cancer fight before surgery
Disease control Recruiting nowThis study tests whether giving a high dose of internal radiation (brachytherapy) before robotic prostate surgery can safely improve outcomes for men with high-risk prostate cancer. About 29 participants will receive the radiation, then surgery, and possibly short-term hormone th…
Phase 1/2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Electric fields plus chemo: new hope for tough pancreatic cancer?
Disease control Recruiting nowThis early-phase trial is testing whether adding tumor treatment fields (TTF) — a device that delivers low-intensity electric fields to disrupt cancer cell division — to a three-drug chemotherapy regimen can safely control metastatic pancreatic cancer. About 40 adults with pancre…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Gut bacteria may hold key to reversing prostate cancer drug resistance
Disease control Recruiting nowThis study tests whether adding dexamethasone or metronidazole to standard therapy can restore sensitivity to abiraterone in men with metastatic prostate cancer that has stopped responding. About 58 men whose cancer progressed on abiraterone will receive either dexamethasone or d…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
One and done? new prostate cancer radiotherapy trial aims to cut treatment to a single session
Disease control Recruiting nowThis study is testing whether a single, high-dose radiotherapy session can safely control prostate cancer in men with intermediate or high-risk disease. About 58 participants will receive one focused radiation dose to the tumor, guided by MRI and imaging. The goal is to see if th…
Sponsor: University of Milano Bicocca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug duo aims to shrink stomach tumors before surgery
Disease control Recruiting nowThis study tests whether adding the drug cadonilimab to standard chemotherapy (SOX) before and after surgery helps people with stomach or gastroesophageal junction cancer that can be removed. About 760 participants will receive either cadonilimab plus chemo or a placebo plus chem…
Phase 3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug cocktail aims to shrink prostate tumors before surgery
Disease control Recruiting nowThis early-phase trial is testing whether a combination of two hormone-blocking drugs (darolutamide and relugolix) can safely shrink high-risk prostate tumors before they are surgically removed. About 30 men with aggressive prostate cancer will take the drugs for a short time bef…
Phase 1 • Sponsor: AdventHealth • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New hope for hard-to-treat stomach cancer? drug duo targets MET gene
Disease control Recruiting nowThis study tests a combination of two drugs, savolitinib and durvalumab, in people with advanced stomach cancer that has a specific gene change called MET amplification. Participants must have already tried at least one chemotherapy that didn't work. The goal is to see if this co…
Phase 2 • Sponsor: Jeeyun Lee • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could adaptive radiation make prostate cancer treatment safer?
Disease control Recruiting nowThis study is testing a new way to deliver radiation for prostate cancer that adapts to daily changes in the body. It involves 100 men with low- or intermediate-risk prostate cancer. The goal is to see if this approach can better protect nearby organs and improve quality of life.
Sponsor: Clinique Sainte Clotilde • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Laser zaps prostate tumors without major surgery
Disease control Recruiting nowThis study tests a new, less invasive way to treat intermediate-risk prostate cancer using a laser guided by micro-ultrasound. The goal is to see if the procedure is safe and can delay or avoid the need for more aggressive treatments like surgery or radiation. Seven men aged 40-8…
Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo aims to revive immune response in lung cancer
Disease control Recruiting nowThis phase 3 trial tests whether a new drug called THIO, given before the immunotherapy cemiplimab, can help people with advanced non-small cell lung cancer who have already tried two prior treatments. About 300 participants will be randomly assigned to receive either the THIO-ce…
Phase 3 • Sponsor: Maia Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New adaptive radiation trial aims to hit cancer harder, spare healthy tissue
Disease control Recruiting nowThis early-phase study tests whether giving extra, MRI-guided radiation after standard treatment is safe and effective for people with rectal cancer. About 37 participants will first receive standard chemoradiation, then get additional radiation that adjusts every two weeks based…
Phase 1 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New vaccine combo aims to boost immune attack on pancreatic cancer
Disease control Recruiting nowThis study tests two different cancer vaccines (GVAX and a KRAS peptide vaccine) given with two immunotherapy drugs (balstilimab and AGEN2373) in people with pancreatic cancer that can be surgically removed. The goal is to find the safest dose and see if the combination helps the…
Phase 1/2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New combo shot targets stomach cancer belly fluid
Disease control Recruiting nowThis study tests whether injecting two drugs directly into the belly can help control fluid buildup (ascites) caused by stomach cancer. The drugs are sintilimab, which helps the immune system fight cancer, and zoledronic acid, which may slow cancer growth. The trial involves 24 a…
Phase 1/2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New radiation technique aims to zap prostate cancer with fewer side effects
Disease control Recruiting nowThis study is testing a new type of radiation therapy called adaptive SBRT for men with intermediate- or favorable high-risk prostate cancer. The goal is to see if it can safely deliver a higher dose of radiation directly to the tumor while avoiding nearby organs, which may reduc…
Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Genetic cheat code may unlock safer, stronger chemo cocktail for tough cancers
Disease control Recruiting nowThis early-stage trial is testing a powerful mix of five chemotherapy drugs for people with advanced upper gastrointestinal cancers, including pancreatic and stomach cancers. The study uses each person's genetic profile to adjust the dose of one of the drugs (irinotecan) to try t…
Phase 1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New antibody drug aims to rally immune system against Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called BA3182 in 168 people with advanced adenocarcinoma, a type of cancer that has spread and cannot be removed by surgery. The drug is a bispecific antibody designed to bring immune cells close to cancer cells so they can be destroye…
Phase 1 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Pancreatic cancer surgery upgrade: remove the whole pancreas, then transplant its own cells to avoid diabetes
Disease control Recruiting nowThis study tests a two-step surgery for people with pancreatic or related cancers. Instead of the standard partial removal, doctors remove the entire pancreas and then transplant the patient's own insulin-making cells into the liver. The goal is to prevent a common complication (…
Phase 1/2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug duo takes on tough prostate cancers
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs—sacituzumab tirumotecan and tagitanlimab—in people with aggressive variant or neuroendocrine prostate cancer that has progressed after prior treatments. The study aims to see if the combo can shrink tumors and delay disease…
Phase 2 • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Jun 26, 2026 18:44 UTC
-
New drug combo offers hope for Hard-to-Treat stomach cancer
Disease control Expanded accessThis program provides early access to zolbetuximab, a targeted drug, combined with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN18.2). Participants must not have had prior chemotherapy or immunotherapy…
Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:18 UTC
-
Can a new tracer make tumors light up on scans?
Diagnosis Recruiting nowThis trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
New imaging agent could light up Hard-to-See cancers
Diagnosis Recruiting nowThis early-phase study tests a new radioactive imaging agent called [68Ga]Ga-DWJ155 in 36 adults with advanced breast cancer or non-small cell lung cancer. The agent is designed to bind to a target on cancer cells and show up on PET scans, helping doctors see where the cancer has…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Aug 29, 2026 00:00 UTC
-
Glow-in-the-Dark dye could help doctors find hidden prostate cancer
Diagnosis Recruiting nowThis early trial tests a fluorescent dye called AS1986NS that aims to make prostate cancer cells glow during a biopsy. Ten men with suspected prostate cancer will receive a tiny dose of the dye before their standard biopsy. The main goal is to check that the dye is safe, not yet …
Phase 1/2 • Sponsor: Antelope Surgical Solutions, Inc • Aim: Diagnosis
Last updated Jul 11, 2026 00:00 UTC
-
New laser microscope could help surgeons save nerves during prostate cancer surgery
Diagnosis Recruiting nowThis study tests a new microscope called LaserSAFE that scans the removed prostate during surgery to see if cancer cells are at the edge. If it works well, surgeons can decide right away whether to spare nearby nerves. About 693 men with prostate cancer will take part, and the st…
Sponsor: University College, London • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
New scan could spot returning prostate cancer at Ultra-Low PSA levels
Diagnosis Recruiting nowThis study is testing whether a special PET scan using flotufolastat F 18 can detect prostate cancer that has come back after surgery, even when PSA levels are very low (0.20 ng/mL or less). Researchers will scan 50 men with a history of prostate cancer and a rising PSA after pro…
Sponsor: Massachusetts General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
Could a special PET scan spot returning prostate cancer sooner?
Diagnosis Recruiting nowThis study is testing whether adding a PSMA PET scan to the usual MRI can better detect prostate cancer that has come back after focal therapy. Focal therapy treats only the cancerous part of the prostate, but cancer can sometimes return. The PSMA PET scan uses a radioactive dye …
Sponsor: University of Chicago • Aim: Diagnosis
Last updated Jun 27, 2026 09:05 UTC
-
Promising new imaging probes could spot prostate cancer missed by standard scans
Diagnosis Recruiting nowThis study tests two new imaging agents (68Ga-G21 and 68Ga-G23) that target a protein found on most prostate cancer cells. The goal is to see if these PET scans can find cancers that standard PSMA scans might miss, helping doctors better stage the disease and guide treatment. Six…
Phase 1/2 • Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
Blood test could spot colon cancer early – 12,000 volunteers needed
Diagnosis Recruiting nowThis study is testing a new blood test called Signal-C that looks for DNA fragments in the blood to detect colorectal cancer and advanced precancerous growths. Researchers will enroll 12,000 people aged 45-84 who are at average risk and already scheduled for a routine screening c…
Sponsor: Universal Diagnostics • Aim: Diagnosis
Last updated Jun 27, 2026 07:56 UTC
-
New PET scan could outshine MRI for prostate cancer detection
Diagnosis Recruiting nowThis study aims to see if a special PET scan (68Ga-PSMA-11) is better than standard MRI at finding prostate tumors in people who have just been diagnosed and haven't started treatment. About 100 participants will receive both scans before surgery, and the results will be checked …
Phase 2/3 • Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
New hope for men battling hot flashes from prostate cancer treatment
Symptom relief Recruiting nowThis study tests a drug called fezolinetant to see if it can reduce hot flashes in men with prostate cancer who are on hormone therapy (androgen deprivation therapy). About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency…
Phase 2 • Sponsor: Shehzad Basaria, M.D. • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
Which gas pump causes less pain during robotic prostate surgery? a Head-to-Head trial
Symptom relief Recruiting nowThis trial compares two devices that inflate the abdomen during robotic prostatectomy for prostate cancer: the AirSeal® Insufflation System and the Stryker PneumoClear Insufflator. The goal is to see which one leads to less pain during and after surgery. One hundred men scheduled…
Sponsor: East and North Hertfordshire NHS Trust • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
Powder during prostate surgery may cut bleeding and save sexual function
Symptom relief Recruiting nowThis study tests whether applying a powder called ARISTA AH during robotic prostate removal can reduce blood loss and help preserve erectile function. About 362 men with prostate cancer will be randomly assigned to receive the powder or standard care. The goal is to see if the po…
Sponsor: St. Antonius Hospital Gronau • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Learning together: new program aims to help couples face prostate cancer
Symptom relief Recruiting nowThis study tests an 8-week program where prostate cancer patients and their spouses learn and support each other using a handbook, a mobile app, and professional guidance. The goal is to improve physical symptoms, emotional well-being, and family resilience. Sixty couples will be…
Sponsor: National Taipei University of Nursing and Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Can less radiation to healthy prostate cut side effects?
Symptom relief Recruiting nowThis study tests whether giving a lower radiation dose to healthy parts of the prostate, while keeping a high dose to visible tumors, can reduce bowel and urinary side effects in men with low or intermediate-risk prostate cancer. Participants will receive two sessions of MRI-guid…
Sponsor: The Netherlands Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Dietary change explored as cancer support strategy
Knowledge-focused Recruiting nowThis early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…
Early phase 1 • Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
12,000 patients needed to bridge gap between clinical trials and Real-World cancer care
Knowledge-focused Recruiting nowThis study aims to collect health information from 12,000 adults with lung or other chest cancers. Researchers want to understand why some people respond better to treatment than others, even when their cancer stage is the same. By gathering data from routine care, they hope to i…
Sponsor: Dutch Society of Physicians for Pulmonology and Tuberculosis • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
New genetic test may predict prostate cancer drug response before surgery
Knowledge-focused Recruiting nowThis study is testing whether a new genetic test (called PCAI ImmunoScore) can predict how well men with high-risk prostate cancer will respond to the drug darolutamide before surgery. About 100 participants will take darolutamide for 3-4 months, then have their prostate removed.…
Phase 2 • Sponsor: Region Stockholm • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Prostate cancer study asks men: what do you think about breast side effects?
Knowledge-focused Recruiting nowThis study interviews 24 men with prostate cancer to learn how they feel about breast-related side effects, such as gynecomastia (enlarged breasts), from treatment. The goal is to understand what matters most to patients when choosing therapies. Results will help design a future …
Sponsor: St Vincent's Hospital, Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Algerian prostate cancer study seeks 2,000 men
Knowledge-focused Recruiting nowThis study aims to describe the characteristics of prostate cancer in Algeria, including patient demographics, symptoms, diagnosis methods, and treatments. Researchers will collect data from 2,000 men aged 19 and older with confirmed prostate cancer. The goal is to better underst…
Sponsor: Société Algérienne de Formation et Recherche en Oncologie • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
PSA after prostate surgery: a crystal ball for cancer?
Knowledge-focused Recruiting nowThis study follows 500 men who had their prostate removed for cancer. Researchers check PSA levels soon after surgery to see if they can predict if the cancer will come back or spread. No new treatments are given—just standard care and observation.
Sponsor: Lithuanian University of Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
1,500 patients to fuel pancreatic cancer research
Knowledge-focused Recruiting nowThis study collects tumor tissue and medical information from 1,500 people with pancreatic cancer. The goal is to build a large biobank that scientists can use to better understand the disease and develop new treatments. Participants undergo standard diagnostic procedures, and no…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Blood tests could predict cancer therapy success
Knowledge-focused Recruiting nowThis study looks for proteins and other markers in the blood of 2000 adults with or suspected of having cancer. The goal is to find markers that may help doctors confirm a cancer diagnosis, choose the right treatment, and predict how well a patient will respond or if the cancer w…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Personalized radiation dosing may improve prostate cancer therapy
Knowledge-focused Recruiting nowThis study looks at whether measuring the exact radiation dose delivered to tumors can predict which patients with advanced prostate cancer will respond to a targeted radioactive therapy called Lu-177 PSMA. Researchers will track 110 men over 12 weeks to see if dose calculations …
Sponsor: Jules Bordet Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
3D model helps surgeons target cancer spread in prostate patients
Knowledge-focused Recruiting nowThis study tests whether a 3D virtual model, created from PSMA PET scans, can help surgeons better remove lymph node metastases in prostate cancer patients. About 102 participants will undergo surgery with the model used for planning and guidance. Researchers will measure how man…
Sponsor: Martini-Klinik am UKE GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
3000 men join quest to unlock prostate Cancer's secrets
Knowledge-focused Recruiting nowThis study is tracking 3000 men with prostate cancer from Guadeloupe and Brittany to understand why the disease progresses differently in different people. Researchers will collect blood, urine, and saliva samples along with health data to look for genetic, environmental, and lif…
Sponsor: Centre Hospitalier Universitaire de la Guadeloupe • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC